Fig. 2From: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort studySensitivity and subgroup analyses of comparative risk for cardiovascular events between SGLT2 inhibitors. BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, HR hazard ratio, LDL low-density lipoprotein, SIPTW stabilized inverse probability of treatment weighting, SMRW standardized mortality ratio weighting, UACR urine albumin–creatinine ratioBack to article page